November 2024 in “Clinical Nutrition Open Science” High doses of resveratrol improve bone cell health and differentiation.
Increased calcium in hair may signal early bone health issues in menopausal women.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
522 citations
,
January 2001 in “Cancer investigation” Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
November 2022 in “Journal of the Endocrine Society” Diagnosing osteoporosis in transgender people is challenging due to unclear guidelines and hormone treatment effects.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
March 2005 in “The Nurse Practitioner” April 2021 in “Institutional Repositories DataBase (IRDB)” High-intensity red LED light boosts bone cell growth and mineralization.
March 2026 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” L-PRF effectively improved healing and bone integration in dental implant surgery.
October 2024 in “International Journal For Multidisciplinary Research” Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.
February 2026 in “Regenerative Biomaterials” Strontium and cerium are most effective for tissue repair.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
15 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Spironolactone effectively treats female pattern hair loss with few side effects.
September 2020 in “Scientific periodicals of Ukraine” "Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
October 2008 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” 5-alpha reductase inhibitors do not increase hip fracture risk.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
1 citations
,
May 2002 in “The Journal of Urology” 1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
58 citations
,
March 2019 in “Frontiers in Pharmacology” Wedelolactone may help treat lung fibrosis by reducing inflammation and lung damage.
25 citations
,
July 2013 in “Environmental Toxicology and Chemistry” Spironolactone harms fish reproduction and is more potent in fish than invertebrates, needing environmental monitoring.
January 2012 in “Journal of Clinical Medicine in Practice” The treatment is safe and effective for elderly patients with advanced non-small-cell lung cancer.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
August 2025 in “Marine Drugs” The new composite material is safe and has anticoagulant properties.
The document's conclusion cannot be provided because the document is not available or cannot be read.
9 citations
,
June 2020 in “Trials” The trial aims to test if spironolactone is an effective acne treatment for women without the side effects of current treatments.
5 citations
,
July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.